2016 – 2017
Accelerating Commercialization grant awarded to RMIT by the Australian Department of Industry, Innovation and Science, with Planet Innovation named as the commercial partner.
Capsule chosen as a finalist in the International AMA Association for Sensor and Measurement – AMA Innovation Award.
Australian Phase I human trial successfully completed on 23 volunteers with results revealing the capsule to be 3,000 times more accurate than breath tests in detecting gas biomarkers.
Atmo Biosciences, with the financial support from Planet Innovation, established to commercialize the capsule.
Atmo Biosciences chosen as an inaugural member of the ANDHealth+ digital health commercialization program.
2018
Atmo Biosciences finalizes licencing deal with RMIT, securing the exclusive worldwide rights to commercialize the capsule. The capsule inventors continue to lead research and development at Atmo, with Planet Innovation’s Commercial Director Mal Hebblewhite taking on the role of CEO.
Research team awarded an NHMRC Development Grant to undertake further research and clinical trials.
Atmo wins Victorian Quickfire Challenge: Driving Device Innovation run by Johnson & Johnson Innovations and the Victorian Government.
2019
The second generation gas sensing capsule begins production at Planet Innovation’s ISO 13485 certified facility in Melbourne, Australia.
Human trial starts at Monash University and the Alfred Hospital investigating the Atmo Gas Capsule’s accuracy in measuring gut motility and transit time, and comparing with other methods. The capsule is also included in another trial with IBS patients.
Former Cochlear CEO Dr. Chris Roberts AO joins the Atmo Board as a Non-Executive Director and accomplished corporate business development.